Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | A Phase I dose escalation study of BiTEs targeting P-cadherin in solid tumors

James Harding, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of a Phase I dose escalation study (NCT02659631) of a bi-specific T-cell engaging therapy targeting P-cadherin in solid tumors. The study did not demonstrate significant anti-tumor activity and high levels of cytokine release syndrome was observed, providing key insight into the management and understanding of immune-related toxicities associated with bi-specific T-cell engaging therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.